Following supportive care including blood transfusion and granulocyte colony-stimulating factor (G-CSF) administration, along with fuzuloparib dose reduction to 100 mg twice daily, the patient continues on maintenance therapy with resolved toxicities (Figure 1), demonstrating grade 1 anemia (hemoglobin 99 g/L) with normalized white blood cell and platelet counts. Here, CSF3 is linked to anemia.